Get 30% Free Customization on This Report

Published Date: October, 2019

Benign Prostatic Hyperplasia Treatment Market (Therapeutic Class - Alpha-blocker, Phosphodiesterase-5 Inhibitor, 5-alpha Reductase Inhibitor, and Other Therapeutic Class; Therapy - Mono Drug Therapy, and Combination Drug Therapy; End User - Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Other End Users): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025


Request Discount Enquire Before Buying

A recent report published by Infinium Global Research on the benign prostatic hyperplasia treatment market provides an in-depth analysis of segments and sub-segments in the global as well as regional benign prostatic hyperplasia treatment market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional benign prostatic hyperplasia treatment market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global benign prostatic hyperplasia treatment market. According to the report, the global benign prostatic hyperplasia treatment market is projected to grow at a CAGR of 8.3% over the forecast period of 2019-2025.

 

Market Insight

Benign prostatic hyperplasia (BPH) is a medical condition involving the expansion of the prostate gland and is highly prevalent in males. It is a non-cancerous growth of the prostate gland originating from the uncontrolled expansion of prostate cells. The common symptoms associated with BPH include frequent urination, urine initiation difficulties, weak urinary system, and inability to empty the urinary bladder.

 

The growing occurrence of benign prostatic hyperplasia coupled with the growing risk factors are the major factors that drive the growth of the benign prostatic hyperplasia treatment market across the globe. Furthermore, the increase in the male geriatric population is the other key factor that augments market growth. According to the United States Census Bureau in 2018, the population of people aged 65 and above in the United States is likely to increase drastically between 2016 and 2060. By 2030, one in five US citizens is expected to be 65 years and older, crossing 78.0 million, out of the total population. However, the high cost of benign prostatic hyperplasia treatment is expected to may restrain the growth of the market. Moreover, the growing preference for in-office based minimally invasive surgical techniques creates an opportunity for the growth of the benign prostatic hyperplasia treatment market in the next few years.

 

In terms of region, North America is expected to dominate the benign prostatic hyperplasia treatment market during the forecast period. This is attributed to factors such as the geriatric population, growing incidences of benign prostatic hyperplasia, and highly structured healthcare industry in the region. Furthermore, increasing the aging population of the United States coupled with a rise in diabetes and obesity is poised to surge the occurrence of benign prostatic hyperplasia and lower urinary tract conditions in the region. Moreover, the Asia Pacific region is projected to grow at a faster rate over the forecast period due to the high population base, growing disposable income, and greater patient awareness about the benign prostatic hyperplasia treatment market.

 

Segment Covered

The report on the global benign prostatic hyperplasia treatment market covers segments such as therapeutic class, therapy, and end user. On the basis of therapeutic class, the sub-markets include alpha-blocker, phosphodiesterase-5 inhibitor, 5-alpha reductase inhibitor, and other therapeutic class. On the basis of therapy, the sub-markets include mono drug therapy, and combination drug therapy. On the basis of end user, the sub-markets include hospitals, specialty clinics, ambulatory surgical centers, and other end users.

 

Companies Profiled:

The report provides profiles of the companies in the market such as Allergan plc, Eli Lilly and Company, Pfizer, Inc., Astellas Pharma, Inc., Abbott Laboratories, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Sanofi, Merck & Co., Inc., and Teva Pharmaceutical Industries Ltd.

 

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of benign prostatic hyperplasia treatment market. Moreover, the study highlights current market trends and provides forecast from 2019-2025. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.

The Infinium Advantages

Analyst Support

Get free analyst support for the queries before and post purchasing report.

Customer Satisfaction

Be assured of 100% customer satisfaction about the research and get 24X7 customer support.

400% Growth

Infinium has achieved over 400%+ growth in its repository and revenue over the last 2 years. Yes, we are proud to say we are growing at a great pace and becoming a trusted partner among our clients.

sign up for our newsletter